Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An improved matrix-type controlled release system for basic fibroblast growth factor

M J Hickey1, W A Morrison

  • 1Microsurgery Research Centre, St. Vincent's Hospital, Victoria, Australia.

Biochemical and Biophysical Research Communications
|June 30, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reuse of a living donor kidney: A case study.

Human immunology·2026
Same author

Testicular immune cell populations and macrophage polarisation in adult male mice and the influence of altered activin A levels.

Journal of reproductive immunology·2020
Same author

Characterization of isolated liver sinusoidal endothelial cells for liver bioengineering.

Angiogenesis·2018
Same author

Composite breast reconstruction: Implant-based breast reconstruction with adjunctive lipofilling.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2017
Same author

Rigid removable cover for dorsal wound protection and tube fixation in pigs.

Australian veterinary journal·2016
Same author

Abstracts of the 24th international isotope society (UK group) symposium: synthesis and applications of labelled compounds 2015.

Journal of labelled compounds & radiopharmaceuticals·2016
Same journal

A transferrin receptor-based vector enables robust Type-II membrane protein display on mammalian cells.

Biochemical and biophysical research communications·2026
Same journal

NAT10-mediated RNA N4-acetylation promotes intestinal fibroblast senescence via DHRS2.

Biochemical and biophysical research communications·2026
Same journal

Deciphering potent MPL activation by the fucose-binding lectin thrombocorticin.

Biochemical and biophysical research communications·2026
Same journal

Mitochondrial genome alterations in cancer: From mutations and epigenetics to targeted therapiesack.

Biochemical and biophysical research communications·2026
Same journal

GPC3 chimeric antigen receptor (CAR)-NK cells combined with Enoblituzumab enhance the anti-tumor efficacy against hepatocellular carcinoma.

Biochemical and biophysical research communications·2026
Same journal

A miR-382-5p-PORCN axis modulates endogenous Wnt signaling during palatal development.

Biochemical and biophysical research communications·2026
See all related articles

A new ethylene vinyl acetate copolymer device effectively releases active basic fibroblast growth factor for over three weeks, improving wound healing and surgical outcomes. This controlled release system offers higher yields than previous methods.

Area of Science:

  • Biomaterials Science
  • Regenerative Medicine
  • Polymer Chemistry

Background:

  • Basic fibroblast growth factor (bFGF) is crucial for wound healing and surgery due to its angiogenic properties.
  • In vivo instability of bFGF limits its therapeutic efficacy.
  • Existing controlled release systems struggle to achieve high yields of active bFGF from permanent matrices.

Purpose of the Study:

  • To develop a novel matrix-type device for sustained and high-yield release of active basic fibroblast growth factor.
  • To overcome the limitations of bFGF instability and low release yields in current delivery systems.

Main Methods:

  • Fabrication of a matrix-type device using ethylene vinyl acetate (EVA) copolymer.
  • Incorporation of basic fibroblast growth factor into the EVA matrix.

Related Experiment Videos

  • Evaluation of the release kinetics and bioactivity of bFGF over an extended period.

    • Main Results:

    • The developed EVA copolymer device successfully released active bFGF for more than three weeks.
    • The yield and duration of active bFGF release significantly surpassed previously reported matrix-type devices.
    • A modified production method for matrix-type devices contributed to the improved release characteristics.

    Conclusions:

    • The novel EVA copolymer device represents a significant advancement in controlled delivery of basic fibroblast growth factor.
    • This system offers enhanced therapeutic potential for wound healing and surgical applications by ensuring sustained release of active bFGF.
    • The improved production method provides a viable strategy for achieving higher yields and longer duration of growth factor release.